# Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

> **NCT02893111** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University General Hospital** · enrollment: 5 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT02893111
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-12-25
- **Final completion:** 2017-01-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893111, "Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02893111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*